NCT00093678 is a NA clinical trial of celecoxib in Cachexia, sponsored by Eastern Cooperative Oncology Group.

Who is sponsoring NCT00093678?

NCT00093678 is sponsored by Eastern Cooperative Oncology Group.

What drugs are being tested in NCT00093678?

Interventions in NCT00093678: celecoxib, anticachectic therapy, nutritional support, pain therapy, supportive care/therapy.

What condition does NCT00093678 study?

NCT00093678 studies Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer, Pain, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific.

Is NCT00093678 still recruiting?

NCT00093678 is currently withdrawn. Last updated 8 October 2015.

Last reviewed 2015-10-08 · How we verify

NCT00093678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer

Withdrawn NA Last updated 8 October 2015

What this trial tests

NA trial testing celecoxib in Cachexia. Withdrawn.

Quick facts

Lead sponsor	Eastern Cooperative Oncology Group
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Masking	double
Primary purpose	supportive care

Drugs / interventions tested

celecoxib (celecoxib) — full drug profile →
anticachectic therapy
nutritional support
pain therapy
supportive care/therapy

Conditions studied

Cachexia — all drugs for Cachexia →
Lymphoma — all drugs for Lymphoma →
Melanoma (Skin) — all drugs for Melanoma (Skin) →
Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Eastern Cooperative Oncology Group

Who can join

Adults 18 to 120, any sex, with Cachexia or Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients. PURPOSE: This randomized clinical trial is studying celecoxib to see how well it works in managing pain, weight loss, and weakness in patients with advanced cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.
Pellerin L, Carrié L, Dufau C, Nieto L, et al · · 2020 · cited 65× · PMID 33121001 · DOI 10.3390/cancers12113147

Verify or expand the search:

Other trials of celecoxib

Trials testing the same drug.

NCT05281276 — Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) · Phase 1 · terminated
NCT05324995 — Peri-Articular-Multimodal Drug and Oral Celecoxib in Management of Postoperative Pain of Total Knee Arthroplasty · Phase 2 · completed
NCT02876094 — Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy · Phase 2 · terminated
NCT02079727 — Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA · Phase 3 · completed
NCT01705106 — Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies · Phase 1 · terminated

Other recruiting trials for Cachexia

Currently open trials in the same condition.

NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
NCT07288619 — Therapeutic Efficacy of Nutritional Supplementation in Cachexia Associated With Chronic Pulmonary Disease · NA · active not recruiting
NCT06989437 — A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif · Phase 2, PHASE3 · recruiting
NCT07130981 — Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients · recruiting

Other Eastern Cooperative Oncology Group trials

Trials by the same sponsor.

NCT07068074 — A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients · Phase 3 · not yet recruiting
NCT07040280 — Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Pati · Phase 2 · not yet recruiting
NCT07122492 — A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude) · NA · not yet recruiting
NCT07085728 — Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatm · Phase 2 · not yet recruiting
NCT06756607 — The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00093678 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eastern Cooperative Oncology Group
Last refreshed: 8 October 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00093678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing